IM Cannabis Corp. (IMCC) Form 6-K — Aug 17, 2026
IM Cannabis Corp. signed a definitive share purchase agreement on August 16, 2026 to sell 100% of I.M.C. Holdings Ltd., which holds its European-focused assets including Adjupharm GmbH, to Slil.com Holding Ltd. Upon closing, IM Cannabis will retain its core Israeli medical cannabis operations.
Key figures
- Eps
- Loss per share C$(2.67) FY2025 and C$(0.85) 6M 2026; pro forma C$(3.58) FY2025 and C$(0.51) 6M 2026
- Revenue
- C$54.731M FY2025 consolidated; C$16.268M for 6M ended June 30, 2026 (consolidated)
- Net Income
- Net loss C$11.750M FY2025; net loss C$6.852M for 6M ended June 30, 2026 (consolidated)
- Outside Date
- September 30, 2026
- Assumed Liabilities Cap
- C$9,400,000
- Pro Forma Net Loss6 M2026
- C$4.191M
- Pro Forma Net Loss FY2025
- C$15.597M
- Pro Forma Revenue6 M2026
- C$7.802M
- Pro Forma Revenue FY2025
- C$18.599M
- Expected Equity Improvement
- approximately C$3.0 million
- Advance Payment Acknowledged
- C$3,000,000
- Weighted Average Shares6 M2026
- 7753651
- Weighted Average Shares FY2025
- 4241321
- European Revenue Removed FY2025
- C$36.132M
- Intercompany Debt Repayment Capital Contribution
- approximately C$10,000,000
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.